Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapy provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

To order this 795+ page report, which features 165+ figures and 270+ tables, please visit this link

The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

 Disease indication

 Non-Hodgkin lymphoma

 Multiple myeloma

 Chronic lymphocytic leukemia

 Acute lymphoblastic leukemia

 Follicular lymphoma

 Mantle cell lymphoma

 Hepatocellular carcinoma

 Colorectal cancer

 Target antigens

 CD19

 BCMA

 CD19, CD22

 GPC3

 EGFR

 Key Geographical Regions

 North America

 Europe

 Asia Pacific

 Latin America

 Middle East and North Africa

 Rest of the World

The report features inputs from eminent industry stakeholders, according to whom T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

 Tim Oldham (Chief Executive Officer, Cell Therapies)

 Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)

 Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)

 Miguel Forte (Chief Operating Officer, TxCell)

 Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)

 Vincent Brichard (Vice President, Immuno-Oncology, Celyad)

 Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

 Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)

 Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)

 Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.

 Autolus

 bluebird bio

 CARsgen Therapeutics

 Celgene (A Bristol Myers Squibb Company)

 Cellectis

 Cellular Biomedicine Group

 Innovative Cellular Therapeutics

 Iovance Biotherapeutics

 Kite Pharma (A Gilead Sciences Company)

 Kuur Therapeutics

 Noile-Immune Biotech

 Novartis

 Shanghai Genechem

 Sinobioway Cell Therapy

 Takara Bio

 Ziopharm Oncology

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

5. Emerging trends on social media

6. Market Landscape

7. Key Insights

8. Clinical Trial Analysis

9. CAR-T Cell Therapy Profiles

10. Key Therapeutic Areas for CAR-T Cell Therapies

11. Partnerships and Collaborations

12. Funding and Investment Analysis

13. Case Study: Cell Therapy Manufacturing

14. Cost Price Analysis

15. Market Sizing and Opportunity Analysis

16. Promotional Analysis

17. Company Profiles

18. Conclusion

19. Conclusion Executive Insights

20. Appendix 1: tabulated data

21. Appendix 2: list of companies and organizations

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email [email protected]

You may also be interested in the following titles:

1. RAS Targeting Therapies Market, 2021-2031

2. Squamous NSCLC Market, 2021-2031

3. Peptide Therapeutics Market, 2021-2031

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/